TORONTO, Canada I June 27, 2014 I Antibe Therapeutics Inc. (TSXV:ATE) announced today that following the receipt of a No Objection Letter from Health Canada last week, its Phase I clinical trial was initiated today. This first clinical study of ATB-346, a drug with the promise of being a safer, anti-inflammatory painkiller, involves safety and pharmacokinetic evaluations in healthy human subjects and will be conducted in Montreal, Canada over the coming months.
Dan Legault, Antibe’s CEO, said, “We are extremely excited to have initiated this study. We wish to thank our development partners for their commitment to ATB-346. Their efforts in working so closely with our team enabled this study to be initiated right after receiving approval from Health Canada. We look forward to continuing ATB-346’s rapid and rigorous clinical development.”
About Antibe Therapeutics Inc.
Antibe Therapeutics Inc. develops safer medicines for pain and inflammation. These medicines are based on Nobel Prize-winning medical research highlighting the crucial role of gaseous mediators, chemical substances produced in the human body, to regulate a range of fundamental cellular processes. The company’s drug design approach involves chemically linking an existing off-patent drug to an Antibe-patented, hydrogen sulfide-releasing molecule. For medical conditions characterized by inflammation or pain, this approach can efficiently produce improved versions of existing drugs.
SOURCE: Antibe Therapeutics
Post Views: 200
TORONTO, Canada I June 27, 2014 I Antibe Therapeutics Inc. (TSXV:ATE) announced today that following the receipt of a No Objection Letter from Health Canada last week, its Phase I clinical trial was initiated today. This first clinical study of ATB-346, a drug with the promise of being a safer, anti-inflammatory painkiller, involves safety and pharmacokinetic evaluations in healthy human subjects and will be conducted in Montreal, Canada over the coming months.
Dan Legault, Antibe’s CEO, said, “We are extremely excited to have initiated this study. We wish to thank our development partners for their commitment to ATB-346. Their efforts in working so closely with our team enabled this study to be initiated right after receiving approval from Health Canada. We look forward to continuing ATB-346’s rapid and rigorous clinical development.”
About Antibe Therapeutics Inc.
Antibe Therapeutics Inc. develops safer medicines for pain and inflammation. These medicines are based on Nobel Prize-winning medical research highlighting the crucial role of gaseous mediators, chemical substances produced in the human body, to regulate a range of fundamental cellular processes. The company’s drug design approach involves chemically linking an existing off-patent drug to an Antibe-patented, hydrogen sulfide-releasing molecule. For medical conditions characterized by inflammation or pain, this approach can efficiently produce improved versions of existing drugs.
SOURCE: Antibe Therapeutics
Post Views: 200
